Antony Mattessich joined Ocular as Chief Executive Officer in August of 2017. Prior to joining the company, he was Managing Director of Mundipharma International based in Cambridge, England. Previous to his time at Mundipharma, Antony ran the U.S. respiratory, dermatology and pediatrics group at Novartis. He also held several positions at Bristol-Myers Squibb, among them, Managing Director roles in Malaysia/Singapore and The Netherlands, and Head of Operations for the International Medicines Group. Antony holds a BA from the University of California at Berkeley and a Masters in International Affairs from Columbia University.